Terms: = Lung cancer AND Neurokinin
46 results:
1. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract] [Full Text] [Related]
2. Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region.
Ide T; Nishino Y; Takiguchi T; Kanda S; Otsuki K; Hayashi R; Yasumoto K; Hirono Y; Makino T; Yano S; Koizumi T
BMC Pulm Med; 2023 Jun; 23(1):228. PubMed ID: 37365528
[TBL] [Abstract] [Full Text] [Related]
3. IFN-α/β-mediated NK2R expression is related to the malignancy of colon cancer cells.
Xiang H; Toyoshima Y; Shen W; Wang X; Okada N; Kii S; Sugiyama K; Nagato T; Kobayashi H; Ikeo K; Hashimoto S; Tanino M; Taketomi A; Kitamura H
Cancer Sci; 2022 Aug; 113(8):2513-2525. PubMed ID: 35561088
[TBL] [Abstract] [Full Text] [Related]
4. Impact of the Oncology Care Model on Use of Supportive Care Medications During cancer Treatment.
Brooks GA; Landrum MB; Kapadia NS; Liu PH; Wolf R; Riedel LE; Hsu VD; Jhatakia Parekh S; Simon C; Hassol A; Keating NL
J Clin Oncol; 2022 Jun; 40(16):1763-1771. PubMed ID: 35213212
[TBL] [Abstract] [Full Text] [Related]
5. neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR.
Zhang XW; Li L; Hu WQ; Hu MN; Tao Y; Hu H; Miao XK; Yang WL; Zhu Q; Mou LY
Cell Death Dis; 2022 Jan; 13(1):41. PubMed ID: 35013118
[TBL] [Abstract] [Full Text] [Related]
6. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract] [Full Text] [Related]
7. Fatigue, Stress, and Functional Status are Associated With Taste Changes in Oncology Patients Receiving Chemotherapy.
Joseph PV; Nolden A; Kober KM; Paul SM; Cooper BA; Conley YP; Hammer MJ; Wright F; Levine JD; Miaskowski C
J Pain Symptom Manage; 2021 Aug; 62(2):373-382.e2. PubMed ID: 33259906
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of active compounds of Chanqin granules on airway neurogenic inflammation induced by PM2.5 in vivo.
Ju Y; Shen R; Yu X
J Tradit Chin Med; 2020 Oct; 40(5):792-802. PubMed ID: 33000580
[TBL] [Abstract] [Full Text] [Related]
9. Aprepitant for Cough in lung cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
Smith JA; Harle A; Dockry R; Holt K; Russell P; Molassiotis A; Yorke J; Robinson R; Birrell MA; Belvisi MG; Blackhall F
Am J Respir Crit Care Med; 2021 Mar; 203(6):737-745. PubMed ID: 32966755
[No Abstract] [Full Text] [Related]
10. Protective effect of diallyl disulfide against cerulein-induced acute pancreatitis and associated lung injury in mice.
Mathan Kumar M; Tamizhselvi R
Int Immunopharmacol; 2020 Mar; 80():106136. PubMed ID: 31991372
[TBL] [Abstract] [Full Text] [Related]
11. Aprepitant for Cough Suppression in Advanced lung cancer: A Randomized Trial.
Noronha V; Bhattacharjee A; Patil VM; Joshi A; Menon N; Shah S; Kannan S; Mukadam SA; Maske K; Ishi S; Prabhash K
Chest; 2020 Jun; 157(6):1647-1655. PubMed ID: 31958446
[TBL] [Abstract] [Full Text] [Related]
12. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
13. Emerging targets for cough therapies; NK1 receptor antagonists.
Badri H; Smith JA
Pulm Pharmacol Ther; 2019 Dec; 59():101853. PubMed ID: 31622673
[TBL] [Abstract] [Full Text] [Related]
14. Co-occurring Gastrointestinal Symptoms Are Associated With Taste Changes in Oncology Patients Receiving Chemotherapy.
Nolden A; Joseph PV; Kober KM; Cooper BA; Paul SM; Hammer MJ; Dunn LB; Conley YP; Levine JD; Miaskowski C
J Pain Symptom Manage; 2019 Nov; 58(5):756-765. PubMed ID: 31349034
[TBL] [Abstract] [Full Text] [Related]
15. Substance P and fibrotic diseases.
Peng L; Agogo GO; Guo J; Yan M
Neuropeptides; 2019 Aug; 76():101941. PubMed ID: 31256921
[TBL] [Abstract] [Full Text] [Related]
16. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.
Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
Trends Pharmacol Sci; 2019 Jul; 40(7):452-463. PubMed ID: 31147200
[TBL] [Abstract] [Full Text] [Related]
17. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
[TBL] [Abstract] [Full Text] [Related]
18. Safety Profile of HTX-019 Administered as an Intravenous Push in cancer Patients: A Retrospective Review.
Walton GD
Adv Ther; 2019 Mar; 36(3):662-669. PubMed ID: 30706408
[TBL] [Abstract] [Full Text] [Related]
19. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in lung cancer.
Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
[TBL] [Abstract] [Full Text] [Related]
20. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
[TBL] [Abstract] [Full Text] [Related]
[Next]
